Skip to main content Accessibility help
×
Home
Hostname: page-component-5d6d958fb5-xnv6z Total loading time: 0.329 Render date: 2022-11-27T17:00:21.585Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": false, "useSa": true } hasContentIssue true

Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review

Published online by Cambridge University Press:  16 April 2020

Panayotis P. Ferentinos
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Beata J. Havaki-Kontaxaki
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Dimitris K. Roukas
Affiliation:
Department of Psychiatry, Eginition Hospital, University of Athens, 74 Vas. Sophias Avenue, 11528Athens, Greece
Get access

Abstract

Approximately 40–70% of treatment-resistant schizophrenic patients fail to benefit from clozapine monotherapy or are partial responders. During the last years several clozapine adjunctive agents have come into clinical practice. This study aims to critically review all published randomized, double-blind, placebo-controlled clinical trials (RCTs) regarding the efficacy and safety of adjunctive agents in clozapine-resistant schizophrenic or schizoaffective patients. A MEDLINE search for RCTs on clozapine adjunctive agents published from January 1980 to February 2004 was conducted. All identified papers were critically reviewed and examined against several methodological features as well as clinical and pharmacological parameters. Eleven trials including 270 patients, partial or non-responders to clozapine, assessed the efficacy of sulpiride, lithium, lamotrigine, fluoxetine, glycine, d-serine, d-cycloserine and ethyl-eicosapentanoate (E-EPA) as clozapine adjuncts. There were eight parallel-group and three crossover trials. The inclusion criteria varied widely. The duration as well as the dosage of clozapine monotherapy were reported adequate in only one trial. Plasma clozapine levels were assessed in only three trials. Main side-effects reported were hypersalivation, sedation, diarrhea, nausea, hyperprolactinaemia. The outcome favored clozapine augmentation with sulpiride, lamotrigine and E-EPA. Lithium was shown to benefit only schizoaffective patients. However, the methodological shortcomings of trials analyzed limit the impact of evidence provided.

Type
Review
Copyright
Copyright ©Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

al-Semaan, Y.Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. Can J Psychiatry 1996; 41: 484485Google ScholarPubMed
American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154Suppl 4163CrossRefGoogle Scholar
Baethge, C., Gruschka, P., Berghofer, A., Bauer, M., Muller-Oerlinghausen, B., Bschor, T., et al.Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 2004; 79: 4350CrossRefGoogle ScholarPubMed
Boyer, P.Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance? Eur Psychiatry 2003; 18: 54S61SCrossRefGoogle Scholar
Breier, A., Buchanan, R.W., Irish, D., Carpenter, W.T. Jr.Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 11451149Google ScholarPubMed
Buchanan, R.W., Kirkpatrick, B., Bryant, N., Ball, P., Breier, A.Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 16251627Google ScholarPubMed
Buckley, P., Miller, A., Olsen, J., Garver, D., Miller, D.D., Csernansky, J.When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27: 615628CrossRefGoogle ScholarPubMed
Carpenter, W.T. Jr., Breier, A., Buchanan, R.W., Kirkpatrick, B., Shepard, P., Weiner, E.Mazindol treatment of negative symptoms. Neuropsychopharmacology 2000; 23: 365374CrossRefGoogle ScholarPubMed
Chong, S.A., Remington, G.Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26: 421440CrossRefGoogle ScholarPubMed
Conley, R.R., Carpenter, W.T. Jr., Tamminga, C.A.Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154: 12431247Google Scholar
Conley, R.R., Kelly, D.L.Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898911CrossRefGoogle Scholar
Dettling, M., Sachse, C., Brockmoller, J., Schley, J., Muller-Oerlinghausen, B., Pickersgill, I., et al.Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berlin) 2000; 152: 8086CrossRefGoogle ScholarPubMed
Dursun, S.M., McIntosh, D., Milliken, H.Clozapine plus lamotrigine in treatment resistant schizophrenia. Arch Gen Psychiatry 1999; 56 950CrossRefGoogle ScholarPubMed
Emsley, R., Myburgh, C., Oosthuizen, P., Van Rensburg, S.J.Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 15961598CrossRefGoogle Scholar
Evins, A.E., Fitzgerald, S.M., Wine, L., Rosselli, R., Goff, D.C.Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157: 826828CrossRefGoogle Scholar
Fenton, W.S., Dickerson, F., Boronow, J., Hibbeln, J.R., Knable, M.A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 20712074CrossRefGoogle Scholar
Freudenreich, O., Goff, D.C.Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323330CrossRefGoogle ScholarPubMed
Goff, D.C., Brotman, A.W., Waites, M., McCormick, S.Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492494Google ScholarPubMed
Goff, D.C., Henderson, D.C., Evins, A.E., Amico, E.A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512514CrossRefGoogle ScholarPubMed
Goff, D.C., Middha, K.K., Sarid-Segal, O., Hubbard, J.W., Amico, E.A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berlin) 1995; 117: 417423CrossRefGoogle ScholarPubMed
Goff, D.C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D.A., et al.A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 2127CrossRefGoogle ScholarPubMed
Henderson, D.C., Goff, D.C.Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57: 395397Google ScholarPubMed
Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M.Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 2936CrossRefGoogle ScholarPubMed
Kane, J., Honigfeld, G., Singer, J.Meltzer H and the Clozaril Collaborative Study Group Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789796CrossRefGoogle ScholarPubMed
Kronig, M.H., Munne, R.A., Szymanski, S., Safferman, A.Z., Pollack, S., Cooper, T., et al.Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152: 179182Google ScholarPubMed
Lieberman, J.A., Safferman, A.Z., Pollack, S., et al.Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 17441752Google ScholarPubMed
Llorca, P.M., Lancon, C., Disdier, B., Farisse, J., Sapin, C., Auquier, P.Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci 2002; 27: 3037Google ScholarPubMed
Mauri, M.C., Volonteri, L.S., Dell'Osso, B., Regispani, F., Papa, P., Baldi, M., et al.Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 2003; 23: 660664CrossRefGoogle ScholarPubMed
Meltzer, H.Y., Burnett, S., Bastani, B., Ramirez, L.F.Effects of 6 months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892897Google Scholar
Peet, M., Brind, J., Ramchand, C.N., Shah, S., Vankar, G.K.Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243251CrossRefGoogle ScholarPubMed
Peet, M., Horrobin, D.F.E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 718CrossRefGoogle Scholar
Perry, P.J., Miller, D.D., Arndt, S.V., Cadoret, R.J.Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231235Google ScholarPubMed
Potkin, S.G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., et al.Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55Suppl B1994 133136Google ScholarPubMed
Potkin, S.G., Jin, Y., Bunney, B.G., Costa, J., Gulasekaram, B.Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145147CrossRefGoogle ScholarPubMed
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., et al.for The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J Med 1997; 337: 809815CrossRefGoogle Scholar
Saba, G., Dumortier, G., Kalalou, K., Benadhira, R., Degrassat, K., Glikman, J., et al.Lamotrigine- clozapine combination in refractory schizophrenia: three cases. J Neuropsychiatry Clin Neurosci 2002; 14: 86CrossRefGoogle ScholarPubMed
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., et al.Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569573CrossRefGoogle ScholarPubMed
Shiloh, R., Zemishlany, Z., Aizenberg, D., Weizman, A.Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case-series study. Eur Psychiatry 1997; 12: 152155CrossRefGoogle ScholarPubMed
Silver, H., Kushnir, M., Kaplan, A.Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol. Psychiatry 1996; 40: 671674CrossRefGoogle Scholar
Small, J.G., Klapper, M.H., Malloy, F.W., Steadman, T.M.Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003; 23: 223228CrossRefGoogle ScholarPubMed
Spina, E., Avenoso, A., Facciola, G., Scordo, M.G., Ancione, M., Madia, A.G., et al.Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berlin) 2000; 148: 8389CrossRefGoogle ScholarPubMed
Spina, E., Scordo, M.G.Newer antipsychotics: Comparative review of drug interactions. Expert Rev Neurotherapeutics 2001; 1: 171182CrossRefGoogle ScholarPubMed
Stahl, S.M., Grady, M.M.A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11: 313327CrossRefGoogle ScholarPubMed
Tiihonen, J., Hallikainen, T., Ryynanen, O.P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., et al.Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 12411248CrossRefGoogle ScholarPubMed
Tsai, G., Yang, P., Chung, L.C., Lange, N., Coyle, J.T.d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 10811089CrossRefGoogle ScholarPubMed
Tsai, G.E., Yang, P., Chung, L.C., Tsai, I.C., Tsai, C.W., Coyle, J.T.d-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 18221825Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.
40
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *